Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma's Appetite for Biologics Platforms Fuels New Company Creation

This article was originally published in Start Up

Executive Summary

With the industry on the cusp of a "me-better" era in biotherapies, Big Pharma has more incentive than ever to invest in novel platforms that can build better biologics. Start-Up profiles ArGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology

You may also be interested in...



Third Rock Leads $30 Mil. Series B For CytomX

The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.

Third Rock Leads $30 Mil. Series B For CytomX

The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.

Open Monoclonal Technology Inc.

From a scientific standpoint, there is little if any need for a new therapeutic antibody manufacturing platform: multiple existing ones generally work well, for those who have licensed rights. But Open Monoclonal Technology Inc. believes its rat-based system has a compelling business advantage: companies coming late to the field can access OMT's technology at relatively low cost, and use it for any targets they wish. OMT itself aims to leverage ownership of the platform to develop antibody "cocktails" or mixtures.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel